Best GLP-1 Telehealth Programs Without Insurance in 2026

Only about 44% of large employers cover GLP-1 medications for weight loss. For everyone else — the self-employed, gig workers, people on plans that exclude obesity medications, or those between jobs — cash-pay telehealth is the most accessible path to treatment.

Why Insurance Often Doesn't Help

Even if you have health insurance, there's a good chance it doesn't cover GLP-1s for weight loss. Many plans cover semaglutide only for its diabetes indication (as Ozempic, not Wegovy). Prior authorization requirements can take weeks and are frequently denied on the first attempt. Some plans have step therapy requirements — you must "fail" other weight loss approaches first. And high-deductible plans may leave you paying $1,000+ per month until you meet your deductible.

The result: millions of clinically eligible patients can't access medications that could meaningfully improve their health because the insurance pathway is either closed or impractical.

Best Options for Uninsured or Under-Insured Patients

Telehealth platforms offering compounded GLP-1s have become the de facto solution for uninsured access. These platforms operate outside the insurance system entirely — no prior authorizations, no formulary restrictions, no denial letters. You pay a monthly fee, see a provider, and receive your medication directly.

What to Look For

When choosing a cash-pay platform, prioritize all-inclusive pricing that bundles provider visits, medication, and shipping. Avoid platforms that charge separately for each component — they often end up more expensive than they appear. Look for flexible commitment terms (month-to-month is ideal), clear cancellation policies, and a refund process if you're medically disqualified after paying.

Brand-Name Options Without Insurance

If you prefer FDA-approved brand-name medications but don't have insurance coverage, manufacturer direct programs are your best bet. Novo Nordisk offers Wegovy injectable at $199/month introductory pricing (through June 2026), and the Wegovy pill at $149/month for the lowest dose. Eli Lilly offers Foundayo (oral tirzepatide) starting at $149/month and Zepbound at reduced pricing through savings cards.

These manufacturer programs require a prescription from a licensed provider — which you can get through a telehealth platform that prescribes brand-name medications.

The Medicare Expansion

Starting July 1, 2026, the Medicare GLP-1 Bridge program will cover GLP-1 medications for eligible Part D beneficiaries with a BMI of 35 or higher. This is a significant expansion — Medicare historically excluded anti-obesity medications. The Bridge program runs through December 31, 2027, with a longer-term BALANCE model potentially following.

If you're on Medicare and meet the criteria, this may be a better financial option than cash-pay telehealth. Talk to your prescriber about eligibility.